Answers are grounded in this paper and cite their sources.
In recent years the the set of diagnostic tools in colorectal cancers has been extended by the assessment of the KRAS gene status. Currently it is a necessary step in order to qualify patients for the targeted therapy. The results of the analysis of several studies revealed a high rate of compliance of the KRAS gene mutational status in primary and metastatic tumors. In this paper we present a rare case of incompatibility of the KRAS mutations in the primary tumor located in the colon and metastatic changes in the liver.
No takes yet. Share an insight, caveat, or question.
Kosakowska et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: